CuraGen and Genentech Sign Research Collaboration Agreement.NEW HAVEN New Haven, city (1990 pop. 130,474), New Haven co., S Conn., a port of entry where the Quinnipiac and other small rivers enter Long Island Sound; inc. 1784. Firearms and ammunition, clocks and watches, tools, rubber and paper products, and textiles are among the many , Conn.--(BUSINESS WIRE)--Nov. 21, 1997--CuraGen Corporation, a Connecticut-based biotechnology company, announced today that it has signed a research collaboration agreement with Genentech, Inc. of South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , CA. Under the agreement, CuraGen and Genentech will collaborate in the discovery of novel therapeutics across a range of disease programs. The collaboration will provide Genentech with access to CuraGen's proprietary genomics platform, including the GeneCalling system for gene expression analysis and gene discovery, the PathCalling system for the discovery of the roles of genes and the proteins they encode (1) To assign a code to represent data, such as a parts code. Contrast with decode. (2) To convert from one format or signal to another. See codec and D/A converter. (3) The term is sometimes erroneously used for "encrypt. in biological pathways, and the GeneScape bioinformatics operating system operating system (OS) Software that controls the operation of a computer, directs the input and output of data, keeps track of files, and controls the processing of computer programs. for web-based project management, data analysis and visualization. This platform will be used to generate GeneCalling and PathCalling data sets from Genentech-specified disease systems. Genentech will also gain non-exclusive access to CuraGen's GeneCalling and PathCalling subscription databases. Under the terms of the agreement, Genentech agreed to purchase $5 million worth of CuraGen stock and to provide up to $26 million in the form of a loan facility. During the term of the agreement, and after the end of the first year, the drawn-down portion of the loan is convertible at CuraGen's option into CuraGen stock at the fair market price. Genentech will additionally provide funding of up to $24 million over five years if the research collaboration and database subscription arrangement are not terminated by Genentech prior to the completion of the full five-year term of the agreement. Genentech has an exclusive right during specified periods to evaluate discoveries arising from the collaboration and to license discoveries upon payment of an additional fee. After the period of exclusivity elapses, rights to genes not licensed to Genentech and rights to the data will revert to CuraGen for inclusion in its subscription databases. Genentech will provide milestone payments and royalties for each therapeutic product that is developed under a license. CuraGen Corporation is developing and applying genomics technologies, processes and information systems to accelerate drug discovery, drug development and pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. . CuraGen established operations in 1993, employed 150 people as of September 30, 1997, including 70 employees with doctoral degrees, and has its principal offices in New Haven, Connecticut, with additional research facilities in Branford, Connecticut Branford is a town located on Long Island Sound in New Haven County, Connecticut, eight miles (13 km) east of New Haven. The population was 29,089 in 2005, according to the U.S. Census Bureau. and Alachua, Florida Alachua is a city in Alachua County, Florida, United States. According to 2006 U.S. Census Bureau estimates, the city's population was 7,554.[2] The city is part of the Gainesville, Florida Metropolitan Statistical Area, which is home to 243,985 people. . CuraGen's technology development has been supported in part by the Advanced Technology Program at the National Institute of Standards and Technology National Institute of Standards and Technology, governmental agency within the U.S. Dept. of Commerce with the mission of "working with industry to develop and apply technology, measurements, and standards" in the national interest. and by the National Institutes of Health. CONTACT: CuraGen Corp. Gregory T. Went, Ph.D. Executive Vice President gwent@curagen.com 1-888-GENOMICS |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion